The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect by April 1.
340B Drug Pricing Program
The AHA today urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect by April 1.
AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.
Good Samaritan, based in Vincennes, Ind., is a county-owned, not-for-profit health system that serves a 10-county rural region across southwest Indiana and southeast Illinois.
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on whether to implement a 340B rebate model program. Comments on the RFI were originally due March 19.
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The court held that Hawaii’s law is not preempted by the federal law, does not…
The Health Resources and Services Administration today said it will extend the deadline to April 20 to receive comments.
HRSA has extended comment deadline and suggested a significantly expanded scope of rebate program.
Hospitals should submit letters to HRSA by March 19.
While the AHA broadly supports the Administration’s objectives as described in the proposed rule, we believe the GLOBE Model as proposed lacks critical operational details that, if not properly clarified, could create additional burden for hospitals and health systems.